Rin Ogiya1, Naoki Niikura2, Hiraku Kumamaru3, Yoshinori Takeuchi4, Takuho Okamura5, Takayuki Kinoshita6, Kenjiro Aogi7, Keisei Anan8, Kotaro Iijima9, Takanori Ishida10, Takayuki Iwamoto11, Masaaki Kawai12, Yasuyuki Kojima13, Takashi Sakatani14, Yasuaki Sagara15, Naoki Hayashi16, Hideji Masuoka17, Masayuki Yoshida18, Hiroaki Miyata3, Hitoshi Tsuda19, Shigeru Imoto20, Hiromitsu Jinno21. 1. Harvard T H Chan School of Public Health, Boston, USA. 2. Department of Breast and Endocrine Surgery, Tokai University School of Medicine, 143, Shimokasuya, Isehara, Kanagawa, Japan. niikura@is.icc.u-tokai.ac.jp. 3. Department of Healthcare Quality Assessment, School of Public Health, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. 4. Department of Biostatistics, School of Public Health, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. 5. Department of Breast and Endocrine Surgery, Tokai University School of Medicine, 143, Shimokasuya, Isehara, Kanagawa, Japan. 6. Division of Breast Surgery, Tokyo Medical Center, Tokyo, Japan. 7. Division of Clinical Research Promotion, NHO Shikoku Cancer Center, Matsuyama, Japan. 8. Department of Surgery, Kitakyushu Municipal Medical Center, Kitakyushu, Japan. 9. Department of Breast Oncology, Juntendo University, Tokyo, Japan. 10. Department of Breast and Endocrine Surgical Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan. 11. Department of Breast and Endocrine Surgery, Okayama University Hospital, Okayama, Japan. 12. Department of Breast Oncology, Miyagi Cancer Center, Natori, Japan. 13. Division of Breast and Endocrine Surgery, Department of Surgery, St. Marianna University School of Medicine, Kawasaki, Japan. 14. Department of Diagnostic Pathology, Nippon Medical School Hospital, Tokyo, Japan. 15. Department of Breast Surgical Oncology, Hakuaikai Medical Cooperation, Sagara Hospital, Kagoshima, Japan. 16. Department of Breast Surgical Oncology, St. Luke's International Hospital, Tokyo, Japan. 17. Kotoni Breast Clinic, Sapporo, Japan. 18. Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan. 19. Department of Basic Pathology, National Defense Medical College, Tokorozawa, Japan. 20. Department of Breast Surgery, Kyorin University Hospital, Mitaka, Japan. 21. Department of Surgery, Teikyo University School of Medicine, Tokyo, Japan.
Abstract
BACKGROUND: Breast cancer survival outcomes vary across different ethnic groups. We clarified the differences in clinicopathological and survival characteristics of breast cancer among Japanese, US residents with Japanese origin (USJ), and US residents with other origins (USO). METHOD: Using Surveillance, Epidemiology, and End Results (SEER) 18 dataset and Japanese Breast Cancer Society (JBCS) registry, we included patients first diagnosed with breast cancer between 2004 and 2015. We categorized the patients into three groups based on the database and the recorded ethnicity: Japanese (all those from the JBCS registry), USJ (those from SEER with ethnicity: Japanese), and USO (those from SEER with ethnicity other than Japanese). Excluding patients diagnosed after 2012, stage 0, and 4 patients, we examined the overall survival (OS) and breast cancer-specific survival (BCSS) using the Kaplan-Meier method and Cox proportional hazards models, adjusting for age, sex, cancer stage, and hormone receptor (HR) status. RESULTS: We identified 7362 USJ, 701,751 USO, and 503,013 Japanese breast cancer patients. The proportion of HR-positive breast cancer was the highest among USJ (71%). OS was significantly longer among Japanese and USJ than USO (Hazard ratio 0.46; 95% Confidence Interval [CI] 0.45-0.47 for Japanese and 0.66 [95% CI 0.59-0.74] for USJ) after adjusting for baseline covariates. BCSS was also significantly higher in the two groups (HR 0.53 [95% CI 0.51-0.55] for Japanese and 0.53 [95% CI 0.52-0.74] for USJ). CONCLUSIONS: In stage I-III breast cancer, Japanese and US residents with Japanese origin experienced significantly longer survival than US residents with non-Japanese origins.
BACKGROUND:Breast cancer survival outcomes vary across different ethnic groups. We clarified the differences in clinicopathological and survival characteristics of breast cancer among Japanese, US residents with Japanese origin (USJ), and US residents with other origins (USO). METHOD: Using Surveillance, Epidemiology, and End Results (SEER) 18 dataset and Japanese Breast Cancer Society (JBCS) registry, we included patients first diagnosed with breast cancer between 2004 and 2015. We categorized the patients into three groups based on the database and the recorded ethnicity: Japanese (all those from the JBCS registry), USJ (those from SEER with ethnicity: Japanese), and USO (those from SEER with ethnicity other than Japanese). Excluding patients diagnosed after 2012, stage 0, and 4 patients, we examined the overall survival (OS) and breast cancer-specific survival (BCSS) using the Kaplan-Meier method and Cox proportional hazards models, adjusting for age, sex, cancer stage, and hormone receptor (HR) status. RESULTS: We identified 7362 USJ, 701,751 USO, and 503,013 Japanese breast cancerpatients. The proportion of HR-positive breast cancer was the highest among USJ (71%). OS was significantly longer among Japanese and USJ than USO (Hazard ratio 0.46; 95% Confidence Interval [CI] 0.45-0.47 for Japanese and 0.66 [95% CI 0.59-0.74] for USJ) after adjusting for baseline covariates. BCSS was also significantly higher in the two groups (HR 0.53 [95% CI 0.51-0.55] for Japanese and 0.53 [95% CI 0.52-0.74] for USJ). CONCLUSIONS: In stage I-III breast cancer, Japanese and US residents with Japanese origin experienced significantly longer survival than US residents with non-Japanese origins.
Entities:
Keywords:
Breast neoplasms; Ethnic groups; Japan; Survival analysis; United states
Authors: Carol E DeSantis; Freddie Bray; Jacques Ferlay; Joannie Lortet-Tieulent; Benjamin O Anderson; Ahmedin Jemal Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-09-10 Impact factor: 4.254
Authors: Rayna K Matsuno; William F Anderson; Seiichiro Yamamoto; Hideaki Tsukuma; Ruth M Pfeiffer; Ken Kobayashi; Susan S Devesa; Paul H Levine Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-07 Impact factor: 4.254